tiprankstipranks
Trending News
More News >
Upstream Bio, Inc. (UPB)
NASDAQ:UPB
US Market
Advertisement

Upstream Bio, Inc. (UPB) AI Stock Analysis

Compare
82 Followers

Top Page

UPB

Upstream Bio, Inc.

(NASDAQ:UPB)

Rating:57Neutral
Price Target:
$12.00
▼(-10.11%Downside)
Upstream Bio, Inc. receives a modest overall stock score of 57. The strong technical indicators provide some optimism, which is offset by significant financial performance challenges and lack of valuation clarity. The company's reliance on external financing and absence of profitability remain key concerns.
Positive Factors
Clinical Trials
Enrollment in the phase 2 VALIANT trial of verekitug in severe asthma has reached completion, which is seen positively, setting up for topline results.
Competitive Advantage
Verekitug is a differentiated, potent, and only anti-TSLP receptor mAb offering with likely Q12W or Q24W dosing, leading to a high likelihood of success.
Financial Position
Upstream Bio is well-financed with $431M cash, offering a unique investment profile.
Negative Factors
Conflict of Interest
Investors should be aware that J.P. Morgan may have a conflict of interest that could affect the objectivity of this report.
Regulatory Risks
There is a potential conflict of interest as J.P. Morgan does business with companies covered in its research reports, including Upstream Bio.

Upstream Bio, Inc. (UPB) vs. SPDR S&P 500 ETF (SPY)

Upstream Bio, Inc. Business Overview & Revenue Model

Company DescriptionUpstream Bio, Inc. (UPB) is a biotechnology company focused on the development of innovative therapies for the treatment of various diseases. Operating within the healthcare and life sciences sectors, Upstream Bio specializes in researching and creating biologic products designed to address unmet medical needs. The company's core services include drug development, clinical trials, and collaboration with research institutions to advance its therapeutic pipeline.
How the Company Makes MoneyUpstream Bio, Inc. primarily generates revenue through the development and commercialization of its proprietary therapies. The company may receive funding from venture capital investments, strategic partnerships, and licensing agreements with larger pharmaceutical companies. Additionally, Upstream Bio might engage in collaborative research and development projects, which can provide milestone payments and royalties based on the success of its therapeutic products in clinical trials and eventual market approval. Government grants and incentives for biotechnology innovation could also contribute to their revenue streams.

Upstream Bio, Inc. Financial Statement Overview

Summary
Upstream Bio, Inc. is experiencing significant operational and cash flow challenges. The income statement reflects minimal revenue growth with ongoing operational losses. The balance sheet is strong due to high equity, but consistent net losses could erode this over time. Cash flow is negative, highlighting reliance on external funding for operations.
Income Statement
45
Neutral
Upstream Bio, Inc. has experienced minimal revenue growth of 95.45% from 2022 to 2023, but revenue decreased slightly by 0.42% from 2023 to 2024. The gross profit margin stands at 100%, reflecting the absence of COGS. However, the company faces significant challenges with negative EBIT and net profit margins, indicating ongoing operational losses.
Balance Sheet
55
Neutral
The company displays a strong equity position with a debt-to-equity ratio of 0.0039 and an equity ratio of 97.55% as of 2024. Despite a high level of stockholders' equity, consistent net losses could erode this strength over time if not addressed.
Cash Flow
50
Neutral
Free cash flow deteriorated from -$19.1 million in 2022 to -$59.7 million in 2024. The company's operating cash flow to net income ratio remains negative, highlighting cash flow challenges. Positive financing cash flow suggests reliance on external funding to manage operations.
BreakdownDec 2024Dec 2023Dec 2022
Income Statement
Total Revenue2.37M2.38M1.21M
Gross Profit2.37M2.38M1.21M
EBITDA-77.67M-40.05M-23.90M
Net Income-62.81M-20.54M-23.87M
Balance Sheet
Total Assets481.72M117.20M18.48M
Cash, Cash Equivalents and Short-Term Investments470.45M109.81M17.05M
Total Debt1.83M45.00K94.00K
Total Liabilities11.87M240.32M124.63M
Stockholders Equity469.85M-123.13M-106.16M
Cash Flow
Free Cash Flow-59.68M-38.07M-19.10M
Operating Cash Flow-59.17M-37.93M-19.02M
Investing Cash Flow-59.48M-82.84M-82.00K
Financing Cash Flow418.91M129.55M9.96M

Upstream Bio, Inc. Risk Analysis

Upstream Bio, Inc. disclosed 81 risk factors in its most recent earnings report. Upstream Bio, Inc. reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Upstream Bio, Inc. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
60
Neutral
$595.14M-37.13%-38.14%29.69%
58
Neutral
$682.73M-115.47%
57
Neutral
$718.15M
57
Neutral
$556.51M-31.46%6.11%-37.79%
52
Neutral
$7.61B0.10-63.03%2.08%16.34%0.32%
48
Neutral
$650.62M34.94%
43
Neutral
$585.06M-115.21%20.58%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
UPB
Upstream Bio, Inc.
13.35
-10.03
-42.90%
TBPH
Theravance Biopharma
11.13
0.88
8.59%
BCYC
Bicycle Therapeutics
8.60
-15.91
-64.91%
PRME
Prime Medicine, Inc.
4.35
-1.26
-22.46%
BCAX
Bicara Therapeutics Inc.
11.93
-13.48
-53.05%
ZBIO
Zenas BioPharma, Inc.
16.32
-1.65
-9.18%

Upstream Bio, Inc. Corporate Events

Executive/Board ChangesShareholder Meetings
Upstream Bio Holds 2025 Annual Stockholders Meeting
Neutral
Jun 12, 2025

Upstream Bio, Inc. held its 2025 Annual Meeting of Stockholders on June 10, 2025, where stockholders voted on two key proposals. The first proposal involved the election of Erez Chimovits and Marcella Kuhlman Ruddy as Class I directors, which was approved. The second proposal was the ratification of PricewaterhouseCoopers LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2025, which was also ratified.

The most recent analyst rating on (UPB) stock is a Buy with a $75.00 price target. To see the full list of analyst forecasts on Upstream Bio, Inc. stock, see the UPB Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 24, 2025